Audentes Therapeutics (BOLD) PT Raised to $52 at Wedbush
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten raised the price target on Audentes Therapeutics (NASDAQ: BOLD) to $52.00 (from $49.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WPP Plc (WPP:LN) (WPP) PT Raised to GBP10.70 at HSBC
- Premier Investments Ltd. (PMV:AU) PT Lowered to AUD26.28 at Credit Suisse
- Nickel Mines Ltd (NIC:AU) PT Lowered to AUD1.10 at Macquarie
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!